SEEL
vs
S&P 500
SEEL
S&P 500
Over the past 12 months, SEEL has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
SEEL vs S&P 500
Performance Gap
SEEL vs S&P 500
Performance By Year
SEEL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Seelos Therapeutics Inc
Glance View
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The firm is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The firm's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. The company is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The firm's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
